2,906 Shares in Vertex Pharmaceuticals Incorporated $VRTX Acquired by Bluebird Wealth Management LLC

Bluebird Wealth Management LLC acquired a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 2,906 shares of the pharmaceutical company's stock, valued at approximately $1,317,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Retirement Planning Group LLC purchased a new position in shares of Vertex Pharmaceuticals in the fourth quarter worth approximately $213,000. Gateway Investment Advisers LLC lifted its holdings in Vertex Pharmaceuticals by 0.3% during the fourth quarter. Gateway Investment Advisers LLC now owns 66,108 shares of the pharmaceutical company's stock valued at $29,971,000 after purchasing an additional 182 shares in the last quarter. Ponta Wealth Partners LLC purchased a new position in Vertex Pharmaceuticals during the fourth quarter valued at approximately $217,000. LaFleur & Godfrey LLC purchased a new position in Vertex Pharmaceuticals during the fourth quarter valued at approximately $219,000. Finally, RFG Advisory LLC purchased a new position in Vertex Pharmaceuticals during the fourth quarter valued at approximately $375,000. Hedge funds and other institutional investors own 90.96% of the company's stock.

Trending Headlines about Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Germany reimbursement for CASGEVY secures payer access for eligible patients (age ≥12) with sickle cell disease and transfusion‑dependent beta thalassemia — a meaningful commercial milestone for a one‑time gene‑editing therapy. Business Wire: CASGEVY reimbursement
• Positive Sentiment: Q1 results: adjusted EPS beat estimates ($4.47 vs. $4.24) and revenue grew ~8% to $2.99B, driven by CF franchise and recently launched products — supports medium‑term revenue trajectory. Zacks: Q1 earnings beat
• Positive Sentiment: Industry recognition: National Kidney Foundation honored Vertex with a 2026 Kidney Biotech Innovation Award — incremental reputational/PR support for non‑CF pipeline work. Yahoo Finance: NKF award
• Neutral Sentiment: Company reiterated 2026 guidance (revenue roughly in line with consensus) — provides stability but limits upside surprise potential. Investor slide deck (Q1)
• Neutral Sentiment: Analysts reacted by trimming price targets while generally remaining constructive — many keep Buy/Outperform ratings but lowered near‑term upside. Benzinga: Analyst revisions after Q1
• Negative Sentiment: Insider selling reported (EVP Joy Liu sold ~1,104 shares; Director Sangeeta Bhatia sold 318 shares) under 10b5‑1 plans — routine but can pressure sentiment when clustered after earnings. InsiderTrades: insider selling
• Negative Sentiment: Market reaction was muted to negative after the quarter: some commentators say the update was “mixed” (beat on EPS but other reads left investors cautious), prompting near‑term profit‑taking. Yahoo: Is it too late to consider VRTX?
• Negative Sentiment: Debate over growth strategy: some analysts/commentators argue Vertex may need bolder M&A to diversify beyond CF and accelerate non‑CF pipeline commercialization — strategic risk that could temper valuation expansion. Seeking Alpha: Q1 review / M&A commentary
• Negative Sentiment: Small insider option grant reported (Michel Lagarde acquired ~$9K in options) — modest signal but immaterial to near‑term share moves. Benzinga: Michel Lagarde options

Insider Activity

In other news, EVP Jonathan Biller sold 945 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $486.35, for a total transaction of $459,600.75. Following the sale, the executive vice president owned 13,659 shares in the company, valued at $6,643,054.65. This trade represents a 6.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Joy Liu sold 1,104 shares of the business's stock in a transaction on Friday, May 1st. The stock was sold at an average price of $425.02, for a total transaction of $469,222.08. Following the completion of the sale, the executive vice president owned 20,729 shares in the company, valued at $8,810,239.58. This represents a 5.06% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 81,853 shares of company stock valued at $38,479,135. Company insiders own 0.20% of the company's stock.

Analyst Ratings Changes

Several equities analysts have weighed in on VRTX shares. Oppenheimer lifted their price target on shares of Vertex Pharmaceuticals from $540.00 to $600.00 and gave the company an "outperform" rating in a report on Tuesday, March 10th. Bank of America lifted their price target on shares of Vertex Pharmaceuticals from $571.00 to $598.00 and gave the company a "buy" rating in a report on Tuesday, March 10th. HC Wainwright lifted their price target on shares of Vertex Pharmaceuticals from $591.00 to $641.00 and gave the company a "buy" rating in a report on Tuesday, March 10th. Truist Financial raised shares of Vertex Pharmaceuticals to a "strong-buy" rating in a report on Monday, April 27th. Finally, UBS Group lifted their price target on shares of Vertex Pharmaceuticals from $535.00 to $545.00 and gave the company a "buy" rating in a report on Monday, January 26th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, Vertex Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $555.17.

Vertex Pharmaceuticals Price Performance

Vertex Pharmaceuticals stock opened at $427.65 on Thursday. The stock has a market cap of $108.78 billion, a P/E ratio of 25.36, a PEG ratio of 1.85 and a beta of 0.30. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $507.92. The firm's 50 day moving average price is $451.70 and its 200-day moving average price is $449.73.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings data on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.24 by $0.23. The firm had revenue of $2.99 billion for the quarter, compared to analysts' expectations of $2.99 billion. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. The company's revenue for the quarter was up 8.3% compared to the same quarter last year. During the same quarter last year, the business posted $4.06 earnings per share. As a group, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 16.81 EPS for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.